Prof. dr. Richard van Hillegersberg, gastro-intestinaal en oncologisch chirurg, UMC Utrecht
Biografie
Education Background
Richard van Hillegersberg attended medical school in Rotterdam, the Netherlands. In 1993 he received his PhD with honor at the Department of Surgery, Erasmus MC in Rotterdam. From 1994-2000, he was trained in General Surgery in Rotterdam. From 2001-2002 he was fellow of Surgical Oncology in the Academic Medical Center and Antoni van Leeuwenhoek Netherlands Cancer Center Amsterdam.
Professional Career
Since 2003 he is appointed as staff surgeon at the University Medical Center Utrecht. From 2009 he is a full professor of gastrointestinal oncology
Honorary member of German Socieity of Surgery, British Society of Endoscopic Surgery, Chilian Society of Surgery
Research/Study Field
• Research is focused on Upper GI minimally invasive and robotic surgery, surgical imaging and genetic profiling. He has authored over 15 chapters in textbooks concerning robotic forgut surgery and over 500 articles in international peer-reviewed journals. He is chairman of the Educational committee and executive board member of the European Society for Diseases for the Esophagus (ESDE) and board member of the of International Society for Diseases for the Esophagus ISDE, he is associate editor of Diseases of the Esophagus and Digestive Surgery, founder and chairman of the Upper GI International Robotic Association (UGIRA).
Samenvatting presentatie
A clinical practice guideline for the definition, diagnosis, and treatment of oligometastatic esophagogastric cancer (OMEC-4).
Introduction: The aim of this study was to provide a clinical practice guideline on the definition, diagnosis, and treatment of oligometastatic esophagogastric cancer, following the recommendations of the OligoMetastatic Esophagogastric Cancer (OMEC) project.
Methods: This guideline was developed according to AGREE II guidelines for clinical practice guidelines. OMEC developed a multidisciplinary European consensus statement for the definition, diagnosis, and treatment of oligometastatic esophagogastric cancer using 3 subprojects including a systematic review, clinical case discussion, and a Delphi consensus study. The OMEC consortium consists of 69 esophagogastric cancer experts, located in 50 cancer expert centers from 17 countries across Europe. The disease-free interval was defined as the time interval between completion of primary tumor treatment and tumor recurrence. Consensus was defined as ³75% agreement on a 5-point Likert scale.
Results: Oligometastatic disease should be considered in esophagogastric cancer patients with 1 organ with ≤3 metastases or 1 involved extra-regional lymph nodng and for restaging after systemic therapy to exclude polymetastatic disease (consensus). Recommended treatment for patients with synchronous or metachronous oligometastatic disease with disease-free interval of ≤2 years was systemic therapy followed by restaging to consider local treatment (consensus).
Discussion: This is the first multidisciplinary European clinical practice guideline for the definition, diagnosis and treatment of oligometastatic esophagogastric cancer. The guideline can be used to standardize inclusion criteria in future clinical trials and could be a crucial step to address the significant variation in treatment approaches for oligometastatic esophagogastric cancer.e station. In addition, oligometastatic disease should be considered in patients without progression after systemic therapy (consensus). 18F-FDG PET/CT imaging is recommended for baseline stagi